From Elephant Ears to Ambr® Waves: A New Path Toward Scale & Abundance for Biomanufactured hMSCs… October 03, 2022 Biomanufacturing, Exosomes / Extracellular Vesicles, MSCs & Characterization
Versatile Manufacturing Formats for Your Adherent Cell Therapy “Triathlon” & Its Bioprocess… August 25, 2022 Biomanufacturing, Bioprocessing
Extracellular Vesicle/Exosome Upstream Process Development: Maximizing Productivity to Accelerate… April 01, 2022 Biomanufacturing, Exosomes / Extracellular Vesicles
Maintaining CQAs as Manufacturing Processes are Scaled from 2D to 3D Bioreactor Culture February 28, 2022 Biomanufacturing, Quality & Regulatory
MSCs “Versus” or MSCs “Via” T Cells for Cell & Gene Therapy? February 07, 2022 Biomanufacturing, Cell Therapy
Establishing a Working Range for Effective MSC-EV Dose December 16, 2021 Biomanufacturing, Cell Therapy, Exosomes / Extracellular Vesicles
“One Does Not Simply Walk Into” a Therapeutic Cell Manufacturing Process… But the Long Road… November 03, 2021 BioEconomy, Biomanufacturing, Bioprocessing, Cell Therapy
What Is Population Doubling Level (PDL) & Why Is It Important for Cell Age? September 29, 2021 Biomanufacturing, MSCs & Characterization
It’s Not Rocket Science – “MSC-EVs” Have the Right Stuff July 14, 2021 Biomanufacturing, Cell Therapy, Exosomes / Extracellular Vesicles, MSCs & Characterization
